Marinus Pharmaceuticals, Inc. - Common Stock (NQ:MRNS)

0.5500 UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 10, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Marinus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

November 09, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

November 07, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY® (ganaxolone) Oral Suspension CV

November 07, 2023

From Marinus Pharmaceuticals

Via Business Wire

Analyst Ratings for Marinus Pharma ↗

September 20, 2023

Via Benzinga

Analyst Ratings for Marinus Pharma ↗

August 11, 2023

Via Benzinga

Earnings Preview: Marinus Pharma ↗

August 09, 2023

Via Benzinga

Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023

October 24, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

October 06, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference

September 21, 2023

From Marinus Pharmaceuticals

Via Business Wire

Analyst Expectations for Marinus Pharma's Future ↗

June 23, 2023

Via Benzinga

The Latest Analyst Ratings for Marinus Pharma ↗

May 30, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 20, 2023

Via Benzinga

Marinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst Event

September 19, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Speakers for Hybrid Investor & Analyst Event on Tuesday, September 19, 2023

September 12, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

September 06, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023

August 17, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

August 11, 2023

From Marinus Pharmaceuticals

Via Business Wire

Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

August 11, 2023

Gainers Amyris, Inc. (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy.

Via Benzinga

Topics Bankruptcy

Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023 ↗

August 11, 2023

Via Benzinga

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

August 10, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder

July 31, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023

July 27, 2023

From Marinus Pharmaceuticals

Via Business Wire

Earnings Scheduled For August 10, 2023 ↗

August 10, 2023

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.

Via Benzinga

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

July 13, 2023

From Marinus Pharmaceuticals

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

June 29, 2023

Via Benzinga

Marinus Pharmaceuticals Announces New Method of Use Patent Granted for IV Ganaxolone by USPTO in Status Epilepticus

June 21, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

June 02, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY® (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder

May 26, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

May 17, 2023

From Marinus Pharmaceuticals

Via Business Wire

Why Heron Therapeutics Shares Are Trading Lower By 34%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

May 12, 2023

Gainers GSI Technology, Inc. (NASDAQ: GSIT) shares surged 108% to $3.4207. GSI Technology is expected to announce financial results for its fiscal fourth quarter after the market close on May 16,...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.